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Many neurodegenerative diseases are related to the propagation and accumulation of toxic proteins
throughout the brain. The lesions created by aggregates of these toxic proteins further lead to
cell death and accelerated tissue atrophy. A striking feature of some of these diseases is their
characteristic pattern and evolution, leading to well-codified disease stages visible to neuropathology
and associated with various cognitive deficits and pathologies. Here, we simulate the anisotropic
propagation and accumulation of toxic proteins in full brain geometry. We show that the same
model with different initial seeding zones reproduces the characteristic evolution of different prion-
like diseases. We also recover the expected evolution of the total toxic protein load. Finally,
we couple our transport model to a mechanical atrophy model to obtain the typical degeneration
patterns found in neurodegenerative diseases.
PACS numbers:
Introduction: Age-related neurodegenerative disorders
are extremely complex and multifaceted pathologies.
Yet, their evolution is known to be closely associated
with the progression of particular protein aggregates.
When these proteins misfold and/or aggregate they can
be transported into the brain tissue and become the
seed for further misfolding and aggregation [1]. Unless
these toxic proteins are removed or stabilized, this chain-
reaction proceeds. As toxic proteins invade the brain and
form larger aggregates, they prevent the proper function
of other proteins and create tissue lesions. over time, it
leads to a disruption of the proper function of the nervous
system, a loss of tissue structure, necrosis, brain atrophy,
and ultimately death [2].
In prion diseases, such as Creutzfeldt-Jakob disease,
the infectious agents are typically small soluble misfolded
isoforms of proteins that can aggregate and trigger the
misfolding of the same protein found in its benign form.
When these aggregates are large enough, they form char-
acteristic tissue lesions. A similar mechanism of pro-
tein corruption and propagation is found in both sec-
ondary injury following traumatic brain injury [3–5] and
common age-related neurodegenerative diseases such as
Alzheimer’s disease, the most common form of demen-
tia [6]. For instance, it is known from in vitro exper-
iments that the amyloid-β protein can form aggregates
that propagate through the tissues. These aggregates
have a distribution of sizes from small soluble groups to
large insoluble fibrils. Their accumulation as plaques is
believed to play a key role in Alzheimer’s disease. Tau
proteins also play an important role in these diseases
[7]. These small proteins are known to stabilize mi-
crotubules within the axon. Hyperphosphorylated tau
proteins can act as seeds for further misfolding and ag-
gregation. These aggregates are found within the axon
where they are rapidly transported through the usual
interneuronal transport mechanisms [17]. They are also
transported from the cell to the extracellular space where
they diffuse through secretion and damage of the host
cell, and from the extracellular space into cells by endo-
cytosis [8, 9]. These aggregates are subject to biological
clearance slowing down or arresting the overall spreading
process. The particular role of neuronal pathways in this
transport mechanism may provide an explanation for the
observation that the spreading of neurofibrillary tangles
follows a characteristic topographic pattern.
a. amyloid-β in Alzheimer’s disease
b. tau inclusions in Alzheimer’s disease
c. α−synuclein inclusions in Parkinson’s disease
d. TPD-43 inclusion in amyotrophic lateral sclerosis
FIG. 1: Typical spatial progression of protein aggregates in
various neurodegenerative diseases. From Jucker [1].
Independently of their molecular origin or specific ac-
tions, these pathologies, known as prion-like diseases,
share the same macroscopic features when viewed as a
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2spatio-temporal evolution process [10]. The progression
is believed to include the following steps: (i) seeding of
misfolded proteins, (ii) templated misfolding and aggre-
gation of native (homologous) proteins, (iii) growth of
aggregates, (iv) fragmentation and spatial propagation
of aggregates of different sizes, (v) assembly of misfolded
proteins into secondary structures (e.g. protofibrils and
fibrils), and (vi) formation of larger tertiary structures
(lesions) at the tissue level. A striking feature of each par-
ticular pathology is its systematic evolution pattern. We
posit that the main reason for such reproducibility is that
the overall progression of the disease is governed by basic
transport processes and that the key difference between
individual diseases, aside from the particular set of pro-
teins involved, is the original location of the seeds, lead-
ing to a characteristic spatio-temporal evolution (Fig. 1)
with respective pathological symptoms.
An essential feature of the dynamics is that small
proteins are preferentially transported transynaptically
but can also diffuse from the extracellular space to the
cells through endocytosis [11]. These effects lead to
fast transport along neuronal pathways and a slower
diffusion in directions perpendicular to the axon bundles.
Here, we couple an anisotropic transport process with
a mechanical model to take into account the relative
effect of seed location, anisotropy, and convoluted brain
geometry on the damage patterns and the resulting
atrophy of brain tissue [12, 13]. We show that a
minimal model for transport and atrophy is sufficient to
recover the main qualitative spatial features of different
neurodegenerative diseases as well as the overall increase
of key biomarkers.
The model: We couple a transport model to a mechani-
cal model of the brain. The geometry of the brain is taken
to be a connected domain Ω in either R2 (slice simulation)
or R3 (full brain simulation) composed of gray (Ωgray)
and white (Ωwhite) matters with different material prop-
erties and total volume (or area) V . We first consider
the transport process. Different models for the aggre-
gation/propagation process have been proposed ranging
from graph Laplacian diffusion on simplified structural
networks [14] to Smoluchowski-type equations [15, 16]
tracking the aggregate-size distribution. Here, we use
a minimal model for the propagation of a toxic protein
that captures the important physical characteristics of
the problem: transformation of existing native proteins
and anisotropic diffusion along axonal pathways. We as-
sume that the concentration c(x, t) ∈ Ωwhite follows the
Fisher-KPP equation
∂c
∂t
= ∇ · (D∇c) + αc(1− c), (1)
where D = d⊥1 + (d‖ − d⊥)γ ⊗ γ is a transversely
anisotropic diffusion tensor chosen to have a preferential
direction along the axon bundle characterized by the unit
vector γ = γ(x, t). Here, α > 0, d⊥ is the regular tissue
diffusion and d‖  d⊥ is the diffusion along the axons.
This model describes the overall increase of toxic protein
concentration, assuming that the pool of protein in the
native form is sufficiently large as not to be affected by
the increase in toxic protein. The nonlinearity provides
a saturation term expressing the maximal concentration
of toxic proteins achievable (taken to be 1 without loss
of generality). In one dimension (along the axonal bun-
dles), the system supports traveling fronts with a velocity
v = 2
√
αd‖ leading to a complete invasion in a charac-
teristic time T = L/v, where L is the typical length scale
for the entire brain, which is on the order of 16cm for hu-
man brains. In the gray matter, for x ∈gray, we assume
simple isotropic diffusion from cells to cells different from
the white matter, (Eq. (1) with d‖ = d⊥ and α = 0).
We are interested in tracking two quantities related to
the concentration field c(x, t). First, the time τ(x, Ccrit)
at which the concentration first reaches a critical level
close to the saturation level Ccrit = (1 − ε) defined im-
plicitly by c(x, τ) = Ccrit. Second, we investigate the
temporal evolution of the average amount of toxic pro-
tein as a possible biomarker, computed as
C(t) =
1
V
∫
Ω
c(x, t) dx. (2)
We couple the transport process to the mechanics of
atrophy by assuming that gray and white matter tissues
are morphoelastic materials [18, 19] and assigning an
isotropic shrinking factor 0 < ϑ < 1 at each point
depending on the concentration of toxic proteins. Given
an initial reference configuration, atrophy is character-
ized by a deformation ϕ : B0 → Bt, x(X, t) = ϕ(X, t)
from the reference brain B0 to the aged brain after
shrinking Bt. Here, x(X, t) is the position at time t
of the material point originally located at X at time
t = 0. This deformation is obtained by first defining
the deformation gradient F = ∇Xϕ and assuming that
it can be decomposed as F = ϑ1/3A, where ϑ denotes
the volumetric change (ϑ < 1 represents shrinking and
ϑ > 1 would correspond to growth). The elastic defor-
mation tensor A, is computed by solving the Cauchy
equation div(T) = 0 for the Cauchy stress tensor
T = J−1A · ∂AW associated with the strain-energy
density W = W (A,x) and J = det(A). The amount
of shrinking is proportional to the total exposure of the
tissue to the toxic proteins, so that ∂tϑ = δc, where
δ > 0 is an overall parameter that describes the rate of
removal of material.
Computational investigation: We create three finite
element models from T2-weighted magnetic resonance
images of a 32-year old male using Simpleware: a two-
dimensional sagittal model, a two-dimensional coronal
model, and a fully three-dimensional, anatomically ac-
curate whole brain model. The sagittal model consists
3of 13442 linear triangular elements and 7216 nodes; the
coronal model consists of 38223 linear triangular elements
and 19813 nodes; and the three-dimensional whole brain
model consists of 401940 linear tetrahedral elements and
80233 nodes. To model anisotropic toxic protein propa-
gation, we register the axonal fiber orientation from the
diffusion tensor magnetic resonance image of the subject
and create an element based fiber-orientation map.
For the initial seeding, we assume a concentration
c(x) = 1 for all x ∈ Ωseed ⊂ Ω and c(x) = 0 other-
wise. Then, using Eq. (1) we propagate the toxic protein
in space and time across the brain with a diffusivity con-
trast of d‖ : d⊥ = 100 to ensure a faster propagation
along the axonal fiber direction. In the white matter, we
use d‖ = 100 mm2/year and α = 0.5/year. In the gray
matter, we use d‖ = d⊥ = 10 mm2/year.
We post-process the concentration field c to extract the
activation time τ(x, Ccrit). From those activation times,
we create activation maps of all four cases of prion-like
disease similar to Fig. 1. Using Eq. (2), from the spatio-
temporal concentration field c(x, t), we extract the inte-
gration of the toxic protein concentration in time C(t) to
create a temporal map of the toxic protein concentration
averaged over the entire brain [20].
Tau inclusions in brains of patients with Alzheimer’s disease
t
t
initial seeding cerebellum
a. b.
c. d.
ventricle
FIG. 2: Activation maps of tau inclusions in brains of patients
with Alzheimer’s disease in a 2D sagittal slice.
Finally, using the tissue atrophy model with different
atrophy rates δ in the gray and white matter tissue,
we utilize our two-dimensional coronal model to create
atrophy maps. It is important to note that atrophy
takes place primarily in locations with elevated con-
centrations of toxic proteins. Therefore, the change of
volume does not significantly affect the time evolution
of the concentration since it is close to maximal at
the locations where atrophy takes place. We take
advantage of this property to compute tissue shrinking
as a post-processing step based on the values of the
concentration at different time points. Since we assume
that after each step of shrinking, there is total relaxation
of the stresses, the mechanical stresses generated are
small during shrinking and we can use a standard
compressible neo-Hookean model valid in small defor-
mations with parameters fitted to experimental data:
W = c1(tr(A
T ·A)− 3) + c2(J − 1)2 with c1 = 666.56 Pa
and c2 = 1777.5 Pa [21]. For the relative shrinking
rate, it is known that the gray matter tissue shrinks
looses more volume than the white matter tissues [22].
For our computation, we use a ratio ϑgray : ϑwhite = 4 : 1.
2D simulations: We start with a two-dimensional
simulation on a sagittal slice (Fig. 2). The region in-
cludes the ventricle and cerebellum but, through no-flux
boundary conditions, it is assumed that no progression
takes place into these regions. Based on the description
of the evolution of tau inclusions in Alzheimer’s disease,
we simulate the propagation of toxic tau proteins by
considering an initial seeding close to the entorhinal cor-
tex (Fig. 2a). We observe the quick progression into the
brain stem and the hippocampus (Fig. 2a), to paralimbic
and adjacent medial-basal temporal cortex (Fig. 2b),
to cortical association areas (Fig. 2c), and eventually
reaching primary sensory-motor and visual areas. The
relatively rapid progression along the hippocampus is
associated with a strong anisotropy along the axonal
pathways tangent to the ventricles. This progression
is consistent with the well-established Braak stages
of Alzheimer’s disease [23]: Stage I-II transentorhinal
(Fig. 2a); Stage III-IV limbic (Fig. 2b); Stage V-VI
isocortical (Fig. 2c-d).
3D simulations: The previous analysis uses a high-
resolution mesh but lacks the three-dimensional geom-
etry of the brain. Next, we use the accepted knowledge
about different neurodegenerative diseases to compare
the progression of various toxic proteins. To test the
specific role of geometry in the progression, we assign
the same parameter values for all cases and only modify
the initial seeding region of the four cases discussed in
[1] and depicted in Fig. 1. For every individual seeding
region we show, in Fig. 3, the time τ to reach a critical
level of damage.
We observe generic progression trends in all cases: (i)
as soon as a sufficient level of toxic proteins reaches the
area close to the ventricles, there is a fast progression
in the limbic system (around the ventricles) leading to
a rapid invasion of the temporal and occipital lobes; (ii)
once a sufficient level of toxic protein is reached within
the cortex, further invasion through the cortex takes
place; (iii) if the parietal lobe is not directly involved
initially, it only becomes invaded in the last stages of the
disease.
4a. amyloid-β in Alzheimer’s disease
b. tau inclusions in Alzheimer’s disease
c. α−synuclein inclusions in Parkinson’s disease
t
t
t
td. TPD-43 inclusion in amyotrophic lateral sclerosis
FIG. 3: Simulated activation maps for the spatial progres-
sion of toxic protein in full brain geometry for various initial
seeding regions matching Fig. 1 [1].
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FIG. 4: Evolution of the total concentration for the simulation
of Fig 2 (2D sagittal slice) and of Fig 3b (3D tau concentration
in Alzheimer’s disease).
An indirect way to follow the evolution of neurodegen-
erative diseases is to look at the averaged concentration
of toxic proteins or associated biomarkers. The paradigm
for this evolution is based on the so-called Jack’s curves.
These curves are the expected, mostly hypothetical,
evolution of a typical biomarker concentration as a func-
tion of time [24]. They take the shape of sigmoid-like
functions: a slow evolution at first during incubation,
followed by a sharp increase during the outbreak and
leading to saturation when the disease is fully established
[20]. The variation of the typical parameters entering
the sigmoids are used to represent physiological quan-
tities such as time of outbreak, and rate of spreading.
These curves serve as a general guideline to understand
the variations between individuals, pathologies, and
the effect of various stimuli or therapeutics [25]. We
can extract these curves from the simulation using
(2) as shown in Fig. 4. Our simulations recover the
predicted behavior for this type of disease integrated
across the entire brain. This profile is not unexpected.
Indeed, we known that Equation (1) supports fronts in
one-dimension that have profile and similar evolution
equations for Alzheimer’s diseases. A simple estimate
using the typical wave speed of front propagation in
one-dimension leads to a lower and upper bound for
the total invasion of 11.3 and 35.8 years, respectively,
obtained by using the front velocity with either the fast
axonal diffusion constant d‖ ≈ 100 mm2/year or the
slow gray matter diffusion constant d ≈ 10 mm2/year.
These estimates are consistent with the characteristic
time scales observed in Fig. 4. Similar curves have also
been obrained on 2D slices in different geometries [16].
Here, we observe that the fully 3D evolution on an
actual brain model also follows the same general trend
of a progressive invasion.
Shrinking: We now turn to the effect of elevated toxic
proteins on the tissue. It is known that the formation of
large aggregates or high concentration of toxic proteins
prevents the proper function of neuronal cells, leading to
ischemia, and eventually tissue removal. For instance, in
the top row of Fig. 5, there is a marked and rapid atro-
phy associated with the disease. We use our propagation
model on a similar coronal slice to compute the activa-
tion time at three different time points (middle row).
For each of these time points we compute the shrinking
of the slice and show the change in geometry from the
previous one (bottom row). The degeneration-induced
atrophy patterns (bottom row) agree well with the at-
rophy pattern observed in Alzheimer’s disease (top row).
Conclusions: Neurodegenerative diseases are known for
their extreme complexity and medical science has wres-
tled with this major challenge by amassing a consider-
able amount of information despite few successes. One
of the remarkable features that appear in these diseases
is their remarkable reproducible topographic propaga-
tion pattern. Each disease has a well-defined spatio-
temporal evolution that has been documented over the
years and catalogued into stages, each associated with
typical symptoms. This evolution appears much more
controlled than other diseases such as cancer and has
led to three main hypotheses in recent years. First, it
has been proposed that diseases share the same charac-
teristics as prion diseases and are based on the seeding,
propagation, and accumulation of toxic proteins involved
5year 0 year 1 year 2 year 3
FIG. 5: Atrophy. Top row: magnetic resonance images show-
ing hippocampal atrophy in Alzheimers disease [26]: yearly
examination of the same subject is shown. Increasing hip-
pocampal and atrophy is observed together with ventricular
enlargement and widening of cortical sulci. Middle row: acti-
vation time based on initial seeding in the brain stem. Bottom
row: shrinking based on the activation time and toxic protein
concentration with a ratio ϑgray : ϑwhite = 4 : 1.
in regular sub-cellular functions such as alpha-synucleins
or tau proteins. Second, it has been proposed that the
overall evolution of a typical biomarker follows regular
sigmoid-like curves. Third, a given disease is associated
with typical atrophy patterns.
There have been multiple mathematical models pro-
posed for neurodegenerative diseases, but most of them
focus on biochemical pathways, cellular interactions,
and the formation of amyloids [27–29]. Our approach
here is radically different as we study the problem at the
largest possible scale of the brain. Our minimal model
takes into account the main microscopic features of these
diseases, but incorporated the full brain geometry and
axonal directions from diffusion tensor imaging. Despite
the complexity of these diseases our model recovers the
three aforementioned key features of neurodegenerative
disease progression and suggests that brain geometry,
transport anisotropy, and mechanics play a central role
in neurodegeneration and atrophy pattern formation.
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